中藥調(diào)控腫瘤相關(guān)巨噬細(xì)胞對肝細(xì)胞癌的治療作用與機(jī)制

打開文本圖片集

基金項目：陜西省中醫(yī)藥管理局中醫(yī)藥科研項目（SZY-KJCYC-2025-JC-004）；秦創(chuàng)原中醫(yī)藥產(chǎn)業(yè)創(chuàng)新聚集區(qū)項目（L2024-QCY-ZYYJQ-Y09）；咸陽市中青年科技領(lǐng)軍人才項目（L2022CXNLRC018）；咸陽市科學(xué)技術(shù)局重點研發(fā)項目（2021ZDYF-SF-0037）

Abstract：Livercancerhasighprevalenceandmortalityratesaroudtheworld，nditsdevelopmentandprogressionareclosely associatedwiththeinteractionbetweenthetumormicroenvironentandtumo-asociatedmacropages（AMs）.TAMsplyasignificant roleinimmunesuprsionimmunesape，cellproliferation，invasion，metastasis，anddugresistaceinlivercanceradiioal Chinesemedicine（TCM），withitsunique therapeuticconceptsandmethods，has showngreatpotentialinregulating TAMsand improvingtheprognosisoflivercancer.Thisarticlereviews theroleand molecular mechanismsof TCMinregulating TAMsforthe treatmentflvecacer，susssteyoleofAsineprogresiooflercancerndanalystepactofeseicinal componentsontherecruitment，polarization，andactivityofTAMsandtheexpresionofrelatedfactorsbasedoTCMtheoryStudies haveshownthatTCMcanregulatetheplarizationstateofTAMs，promoteteformationofM-typeatitumormacropages，ndiibit theactivityofM2-typetumormacrophages，therebyplayingaroleininhibitingtheproliferationoflivercancercels，promoting apoptosis，inbitingagiogenesis，andehancingimmuneresponse.Inaddition，tisarticlealsosummaresthemoleularargetnd mechanisms ofactionof TCMmonomers，compound prescriptions，andnovel preparations inthe treatmentof livercancer，suchas inhibitigthesecretionofcyokinesbyTAMs，regulatingsignalingpathways，andectingmetabolicpathways，inordertoprovidea scientific basis fortheapplicationofTCMinlivercancertreatmentandofernewideas forimmunotherapyforlivercancer.

Key Words：Liver Neoplasms；Tumor-Associated Macrophages；Traditional Chinese Drugs

Research funding：TraditionalChinese Medicine ScientificResearchProjectofShanxiProvincialAdministrationofTraditional Chinese Medicine（SZY-KJCYC-2O25-JC-004）；QinChuangyuan Traditional ChineseMedicineIndustryInnovationAggregation ZoneProject（L2024-QCY-ZYYJJQ-Y09）；YoungandMiddle-aged Scientificand TechnologicalLeading TalentsProjectof Xianyang City（L2022CXNLRC018）；KeyR&DProjectof Xianyang Science andTechnology Bureau（2021ZDYF-SF-0037）

肝細(xì)胞癌（HCC）作為全球性高發(fā)病率、高病死率的疾病，其發(fā)病機(jī)制涉及病毒性肝炎、長期飲酒、非酒精性脂肪性肝病等多個因素[1]。（剩余21970字）